Transparency Market Research

Pulmonary Arterial Hypertension (PAH) Market Was Valued at US$4.04 Billion in 2013 and Is Expected Reach US$5.19 Billion in 2020

Transparency Market Research Announced Report Title "Pulmonary Arterial Hypertension (PAH) Market (Prostacyclin and Prostacyclin Analogs, ERAs, PDE-5 Inhibitors, sGC Stimulators and Selexipag) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" And Its Full Database.


Albany, NY -- (SBWIRE) -- 09/01/2015 -- The global pulmonary arterial hypertension market is expected to rise proportionate to the rise in the number of heart failures. Pulmonary arterial hypertension is characterized by restrained blood flow via the pulmonary arteries, which leads to a constant increase in pulmonary vascular resistance and finally failure of the right side of the heart. PAH is one of five groups of pulmonary hypertension, as described by the World Health Organization (WHO). PAH develops due to the narrowing, blocking, and thickening of the pulmonary arteries.

Browse Full Global Pulmonary Arterial Hypertension Market Report With Complete TOC @

Advanced treatment of PAH includes prostacyclin and prostacyclin analogs, phosphodiesterase-5 (PDE-5) inhibitors, endothelin receptor antagonists (ERAs) and soluble guanylate cyclase (sGC) stimulators. This leading therapy is aimed towards the symptoms of PAH and is not directed at the fundamental cause of PAH. In addition to the aforementioned classification of drugs, there are some other drugs prescribed to patients suffering from PAH, such as diuretics, calcium channel blockers, anticoagulants, and digoxin.

The pulmonary arterial hypertension (PAH) market was valued at US$4.04 billion in 2013 and is expected reach US$5.19 billion in 2020, expanding at a CAGR of 2.3% between 2014 and 2020.

Uptravi: A New Drug Application in Patients with Pulmonary Arterial Hypertension

Categorized on the basis of substantially applicable drug categories, the global pulmonary arterial hypertension (PAH) market has been segregated into prostacyclin analogs and prostacyclin, endothelin receptor antagonists (ERAs) and soluble guanylate cyclase (sGC) stimulators. Prostacyclin and prostacyclin analogs were the foremost to be medically endorsed by the U.S. FDA to treat PAH. Presently, epoprostenol Veletri and Flolan, treprostinil (Tyvaso, Remodulin, and Orenitram), and iloprost (Ventavis) are the three primary drugs in this category, and are widely used in the treatment for patients with PAH. A new drug called Uptravi, which is an assorted IP prostacyclin antagonist, is predicted to come to the fore by 2016. This new drug is expected to augment the growth of the market for prostacyclin analogs and prostacyclin through the forecast period from 2014 to 2020.

Opsumit: The Highest Selling Pulmonary Arterial Hypertension Drug

Endothelin receptor antagonists (ERAs) that disrupt the interaction between endothelin receptors and endothelin have materialized as one of the primary segments in the treatment of PAH. Tracleer (bosentan) is the foremost FDA-certified ERA. Opsumit (macitentan) and Letairis/Volibris (ambrisentan) are some other certified ERAs for the treatment of PAH. Among these, Opsumit was certified by the European Commission and the U.S. FDA in December 2013. Opsumit is predicted to materialize as the highest selling PAH drug by the end of 2020. Tracleer is set to be off-patent in Europe and the U.S. in 2017 and 2015, respectively. Patent termination of Tracleer is expected to constitute a big setback in the advancement of the ERAs market from 2014 to 2020.

Adempas: The only Certified Stimulator by the U.S. FDA to Treat Pulmonary Hypertension

Adcirca (tadalafil) from Eli Lilly/United Therapeutics Corporation and Revatio (sildenafil) from Pfizer, Inc., are the FDA-certified PDE-5 inhibitors used for the treatment of PAH. Adempas (riociguat) is the only approved sGC blockage used for the treatment of PAH. Adempas is devised for the treatment of PAH by stimulation of nitric oxide receptor sGC, which causes vasodilation, relieving the pressure on arterial walls. Adempas was first certified by the U.S. FDA in October 2013. Throughout the forecast period from 2014 to 2020, riociguat would undergo extreme competition from drugs such as treprostinil and macitentan, as all of them are meant for oral application.

Leading players in the global pulmonary arterial hypertension (PAH) market include United Therapeutics Corporation, Gilead Sciences, GSK Plc, and Actelion Pharmaceuticals, Ltd. Among these, Actelion Pharma held the biggest share in the global PAH market in 2013 thanks to its top-selling product, Tracleer (bosentan).

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

North America

Asia Pacific


Middle East and Africa

Latin America

This report provides comprehensive analysis of

Market growth drivers

Factors limiting market growth

Current market trends

Market structure

Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter's five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

It provides distinctive graphics and exemplified SWOT analysis of major market segments

Get Sample Report:

About Transparency Market Research (TMR)
Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030